Marinus H. J. van Oers

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert Marcus et al. · Blood · 2006 · 592 citations · Full text

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

Franck Morschhauser, John Radford, Achiel Van Hoof et al. · Journal of Clinical Oncology · 2008 · 458 citations

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Bertrand Coiffier, Stéphane Leprêtre, Lars Møller Pedersen et al. · Blood · 2007 · 383 citations

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H. J. van Oers, M. van Glabbeke, L. Giurgea et al. · Journal of Clinical Oncology · 2010 · 336 citations

Complement activation plays a key role in the side‐effects of rituximab treatment

Lizet E. van der Kolk, A.J. Grillo-López, Joke W. Baars et al. · British Journal of Haematology · 2001 · 322 citations · Full text

Key Role, Immunology, Pathology +17